Načítá se...
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). METHODS: We mined...
Uloženo v:
| Vydáno v: | Cardiovasc Diabetol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7879696/ https://ncbi.nlm.nih.gov/pubmed/33573667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01243-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|